Burden of brain and other central nervous system cancer in China, 1990–2019: a systematic analysis of observational data from the global burden of disease study 2019

Hou, Xinran; Song, Zongbin; Zhang, Fan; Liu, Zhuoyi; Long, Wenyong; Long, Zheng; Zhou, Maigeng; Wang, E; Yin, Peng; Zhu, Maoen

doi:10.1136/bmjopen-2021-059699

Cited by 4 publications

(4 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consistent with previous studies elsewhere (4,7,14), our study also found an increase in ASIR in China and the US over time. The increase in ASIR was more significant in China compared to the United States, which might be related to the growing aging population and improved imaging techniques in China (30,31).…”

Section: Discussionsupporting

confidence: 93%

“…Previous studies have focused on temporal trends in brain cancer burden without investigating the effects of age, period, and cohort on brain tumor burden, there was no comparative study on epidemiological trends and impact factors (e.g., age, period, and cohort) between China and the US (4,14,15). The Global Burden of Disease (GBD) study included extensive epidemiological data on the disease since 1990, allowing us to compare the burden of brain tumors in China and the US.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The comparative burden of brain and central nervous system cancers from 1990 to 2019 between China and the United States and predicting the future burden

Huang

Yan

et al. 2022

Front. Public Health

View full text Add to dashboard Cite

BackgroundBrain and central nervous system (CNS) cancers represent a major source of cancer burden in China and the United States. Comparing the two countries' epidemiological features for brain and CNS cancers can help plan interventions and draw lessons.MethodsData were extracted from the Global Burden of Disease repository. The average annual percentage change (AAPC) and relative risks of cancer burdens were calculated using joinpoint regression analysis and age-period-cohort (APC) models, respectively. Moreover, a Bayesian APC model was employed to predict the disease burden over the next decade.ResultsFrom 1990 to 2019, the number of incidences, deaths, and disability-adjusted life-years (DALYs) increased in China and the US, with a larger increase in China. Age-standardized incidence rates in China and the United States have shown an increasing trend over the past three decades, with AAPCs of 0.84 and 0.16%, respectively. However, the rates of age-standardized mortality and age-standardized DALYs decreased in both countries, with a greater decrease in China. Overall, age trends in cancer burden were similar for males and females, with two peaks in the childhood and elderly groups, respectively. The period and cohort effects on incidence showed an overall increasing trend in China and limited change in the US. However, the period effects for mortality and DALY were decreasing in both countries, while the cohort effects tended to increase and then decrease. Moreover, we predicted that the cancer burdens would continue to rise in China over the next decade.ConclusionThe burden of brain and CNS cancers is substantial and will continue to increase in China. Comprehensive policy and control measures need to be implemented to reduce the burden.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Introductionmentioning

confidence: 99%

The comparative burden of brain and central nervous system cancers from 1990 to 2019 between China and the United States and predicting the future burden

Huang

Yan

et al. 2022

Front. Public Health

View full text Add to dashboard Cite

show abstract

“…With declines in the population seroprevalence of HBV and HCV, as well as a reduction in aflatoxin exposure, liver cancer rates have been declining steadily in many high‐risk countries in East and South‐Eastern Asia since the late 1970s and in Japan and China since the 1990s 63,125,126 . Vaccination against HBV has markedly reduced the prevalence of HBV infection and the incidence of HCC in high‐risk countries in East Asia, where it was first introduced in the early 1980s 127 .…”

Section: Resultsmentioning

confidence: 99%

Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Bray,

Laversanne,

Sung

et al. 2024

CA A Cancer J Clinicians

View full text Add to dashboard Cite

This article presents global cancer statistics by world region for the year 2022 based on updated estimates from the International Agency for Research on Cancer (IARC). There were close to 20 million new cases of cancer in the year 2022 (including nonmelanoma skin cancers [NMSCs]) alongside 9.7 million deaths from cancer (including NMSC). The estimates suggest that approximately one in five men or women develop cancer in a lifetime, whereas around one in nine men and one in 12 women die from it. Lung cancer was the most frequently diagnosed cancer in 2022, responsible for almost 2.5 million new cases, or one in eight cancers worldwide (12.4% of all cancers globally), followed by cancers of the female breast (11.6%), colorectum (9.6%), prostate (7.3%), and stomach (4.9%). Lung cancer was also the leading cause of cancer death, with an estimated 1.8 million deaths (18.7%), followed by colorectal (9.3%), liver (7.8%), female breast (6.9%), and stomach (6.8%) cancers. Breast cancer and lung cancer were the most frequent cancers in women and men, respectively (both cases and deaths). Incidence rates (including NMSC) varied from four‐fold to five‐fold across world regions, from over 500 in Australia/New Zealand (507.9 per 100,000) to under 100 in Western Africa (97.1 per 100,000) among men, and from over 400 in Australia/New Zealand (410.5 per 100,000) to close to 100 in South‐Central Asia (103.3 per 100,000) among women. The authors examine the geographic variability across 20 world regions for the 10 leading cancer types, discussing recent trends, the underlying determinants, and the prospects for global cancer prevention and control. With demographics‐based predictions indicating that the number of new cases of cancer will reach 35 million by 2050, investments in prevention, including the targeting of key risk factors for cancer (including smoking, overweight and obesity, and infection), could avert millions of future cancer diagnoses and save many lives worldwide, bringing huge economic as well as societal dividends to countries over the forthcoming decades.

show abstract

“…According to GBD 2019, the global mortality and YLLs rates caused by CNS cancer were 3.18 and 110.25, significantly lower than our results. Another research scoped at the national level indicated that in 2019, there were approximately 63527 deaths in China, with an ASMR of 3.5 (2.62–4.21), which decreased by 9.6% from 1990 to 2019 [ 20 ]. In recent years, studies on the local burden of CNS cancer in other areas of China have been scarce.…”

Section: Discussionmentioning

confidence: 99%

Mortality and Years of Life Lost Due to Brain and Other Central Nervous System Cancer in Wuhan, China, from 2010 to 2019

Chen

Liu

Wen

et al. 2023

IJERPH

View full text Add to dashboard Cite

Background: Brain cancer is one of the worst types of cancer worldwide. Understanding the epidemiology of CNS cancer is critical for properly allocating healthcare resources. Methods: We collected data on CNS cancer deaths in Wuhan, China, during 2010–2019. We constructed the cause-eliminated life tables to calculate life expectancy (LE), mortality, and years of life lost (YLLs) by age and sex. The BAPC model was used to forecast the future trends of age-standardized mortality rate (ASMR). Decomposition analysis was adopted to explore the contribution of population growth, population aging, and age-specific mortality to the change in total CNS cancer deaths. Results: In 2019, the ASMR of CNS cancer was 3.75, and the ASYR was 135.70 in Wuhan, China. ASMR was expected to decrease to 3.43 in 2024. The age distribution of deaths due to CNS cancer was concentrated in the middle-aged and older population, with a peak in the 65–69 age group. Caidian, Jianghan, and Qingshan had the greatest ASMRs in 2019 in Wuhan, with ASMRs of 6.32, 4.78, and 4.75, respectively. Population aging is critical to the change in total CNS cancer deaths. Conclusion: We analyzed the current status, temporal trends, and gender and age distributions of the burden of CNS cancer in Wuhan, during 2010–2019, providing a valuable reference for better lessening the CNS cancer burden.

show abstract

Burden of brain and other central nervous system cancer in China, 1990–2019: a systematic analysis of observational data from the global burden of disease study 2019

Cited by 4 publications

References 34 publications

The comparative burden of brain and central nervous system cancers from 1990 to 2019 between China and the United States and predicting the future burden

The comparative burden of brain and central nervous system cancers from 1990 to 2019 between China and the United States and predicting the future burden

Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Mortality and Years of Life Lost Due to Brain and Other Central Nervous System Cancer in Wuhan, China, from 2010 to 2019

Contact Info

Product

Resources

About